ERBB2 and neoplasm: Treatment with IgA anti-HER2 or IgA anti-EGFR anti-tumor mAbs resulted in significantly enhanced anti-tumor cytotoxicity in FcαRI transgenic mice compared to WT littermates, which was mediated by FcαRI-expressing macrophages (210, 211).